ArticleOncotarget2016
Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Interferon regulatory factor 1 enhances T cell differentiation in patients with myasthenia gravis.Neural regeneration research · 2026Article
- Tertiary Lymphoid Structure: A Potential Therapeutic Target Affecting Immune Response in Autoimmune Diseases.Clinical reviews in allergy & immunology · 2026Review
- MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis.The Journal of clinical investigation · 2025Article
- Circulating inflammatory cytokines and the risk of myasthenia gravis: a bidirectional Mendelian randomization study.BMC neurology · 2025Article
- Development of a refined experimental mouse model of myasthenia gravis with anti-acetylcholine receptor antibodies.Frontiers in immunology · 2025Article
- Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis.Journal of neuroinflammation · 2023Article
- Article
- Review
- Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases.Frontiers in immunology · 2022Review
- Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.Therapeutics and clinical risk management · 2022Review
- Intrathymic Plasmablasts Are Affected in Patients With Myasthenia Gravis With Active Disease.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination.Frontiers in immunology · 2021Review
- The Multifaceted Roles of B Cells in the Thymus: From Immune Tolerance to Autoimmunity.Frontiers in immunology · 2021Review
- Decreased expression of miR-29 family associated with autoimmune myasthenia gravis.Journal of neuroinflammation · 2020Article
- New Approaches to Targeting B Cells for Myasthenia Gravis Therapy.Frontiers in immunology · 2020Review
- Thymic B Cells Promote Germinal Center-Like Structures and the Expansion of Follicular Helper T Cells in Lupus-Prone Mice.Frontiers in immunology · 2020Article
- Article
- Chronic Inflammation: A Common Promoter in Tertiary Lymphoid Organ Neogenesis.Frontiers in immunology · 2019Review
- Regulative role of the CXCL13-CXCR5 axis in the tumor microenvironment.Precision clinical medicine · 2018Review
- The correlation of neutrophil-to-lymphocyte ratio with the presence and activity of myasthenia gravis.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal overexpression of CXCL13 is observed in many inflamed tissues and in particular in autoimmune diseases. Myasthenia gravis (MG) is a neuromuscular disease mainly mediated by anti-acetylcholine receptor autoantibodies. Thymic hyperplasia characterized by ectopic germinal centers (GCs) is a common feature in MG and is correlated with high levels of anti-AChR antibodies. We previously showed that the B-cell chemoattractant, CXCL13 is overexpressed by thymic epithelial cells in MG patients. We hypothesized that abnormal CXCL13 expression by the thymic epithelium triggered B-cell recruitment in MG. We therefore created a novel transgenic (Tg) mouse with a keratin 5 driven CXCL13 expression. The thymus of Tg mice overexpressed CXCL13 but did not trigger B-cell recruitment. However, in inflammatory conditions, induced by Poly(I:C), B cells strongly migrated to the thymus. Tg mice were also more susceptible to experimental autoimmune MG (EAMG) with stronger clinical signs, higher titers of anti-AChR antibodies, increased thymic B cells, and the development of germinal center-like structures. Consequently, this mouse model finally mimics the thymic pathology observed in human MG. Our data also demonstrated that inflammation is mandatory to reveal CXCL13 ability to recruit B cells and to induce tertiary lymphoid organ development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.